Nihon Medi-physics Company, Limited

Other

Hitachi, Ltd.

Nippon Unicar Company Limited

Asaca Corporation

Nof Corporation

Union Carbide Corporation

Mitsubishi Chemical Corporation

Kuraray Co., Ltd.

Topcon Corporation

Ge Healthcare Limited

Kagoshima University

Kinzolu Kako Gijutsu Kenkyusho Co., Ltd.

Zenken Co., Ltd.

Akio Hayashi

Masahito Toyama

Fumie Kurosaki

Toshiyuki Shinmura

Osamu Ito

Arinori Harano

Kazushige Hiroi

Daisaku Nakamura

Mitsuru Akashi

Itaru Nonomura

Kiroku Tsukada

Akitaka Senuma

Hitoshi Nakamura

Koutaro Onso

Toshiyuki Nagai

Yasuhiro Furukawa

Yoshiyuki Nakayama

Tomohisa Kohiyama

Yukio Fujii

Kenjiro Mori

Tetsushi Taguchi

Yoshifumi Fujikawa

Isao Noda

Atsuo Kawaguchi

Katsuhiro Horita

Seiho Taniguchi

Norikazu Sasaki

Soichi Nakamura

Akio Kishida

Emi Kaneko

Kunio Kotani

Jun Toyohara

Kouichi Shibasaki

Ryuzo Hosotani

Riri Ueda

Kenji Watanabe

Koichi Ogawa

Shinji Kimura

Kazuhiko Ishihara

Nobuo Nakabayashi

Ken Suzuki

Yuji Ito

Anthony Eamon Storey

Wataru Ninomiya

Koji Ishihara

Masataka Okayama

Toshihiko Ohta

Tetsuya Yoshioka

Yoshishige Murata

Makoto Saika

Yoko Tatara

Norio Watanabe

Takeo Tomokane

Koichi Inoue

Kenshiro Shuto

Nobuo Takahashi

Shinji Tanaka

Toshio Hasegawa

Harumi Morino

Shigeru Kitano

Daijiro Shiino

Shinya Takasaki

Shigeyuki Tanifuji

Yoshinari Shoyama

Denis Raymond Christophe Bouvet

Kazuo Matsuyama

Shozo Nakagawa

Hiroki Fukui

Norihito Nakata

Masaya Fujisue

Junichi Seki

Yoshihito Kadoma

Kohichi Nakatani

Katsuhiko Tanaka

Shinji Tokunaga

Takafumi Yukimori

Noritada Kuwayama

Kenichiro Nakamoto

Kensaku Sonoda

Hidemi Tachikawa

Norimichi Kawabe

Soichi Takasaki

Hiroshi Suzuki

Tsutomu Oishi

Yutaka Satoh

Yousuke Yamada

Yoshio Fujioka

Ryuichi Isono

Junzo Sunamoto

Koichi Okabe

Kazunari Akiyoshi

An ophthalmologic apparatus includes a subjective measurement optical system configured to measure a subjective refractive value of a subject eye; an objective measurement optical system configured to measure objective refractive characteristics of the subject eye; and a controller configured to control the subjective measurement optical system and the objective measurement optical system. The controller is further configured to perform measurement of the objective refractive characteristics of the subject eye by the objective measurement optical system and perform objective monitoring to monitor objective measurement information obtained by the measurement of the objective refractive characteristics during a weakest power test in which a weakest point is being obtained by the subjective measurement optical system, a maximum visual acuity value or a set predetermined visual acuity value being readable from the weakest point.

Ophthalmologic apparatus for determining whether accommodation intervention by subject eye has occurred

The present invention is a catalyst comprising:

Catalyst, method for preparing catalyst, and method for producing unsaturated carboxylic acid and/or unsaturated carboxylic acid ester

The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.

Site-specific radioisotope-labeled antibody using IgG-binding peptide

It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; Ris an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by &#x2014;OR; Ris a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and Ris a protective group.

Precursor compound of radioactive halogen-labeled organic compound

It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula:  wherein n is an integer of 0 or of 1 to 4; Ris an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by &#x2014;OR; Ris a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and Ris a protective group.

A composition including a radioactive fluorine-labeled amino acid compound is provided, which can be prevented from radiolysis. Disclosed is a composition which includes a solution containing a radioactive fluorine-labeled amino acid compound as an effective ingredient, in which the pH value of the solution is kept at 2.0-5.9, more preferably 2.0-4.9 in order to inhibit radiolysis. Also, it is possible to further inhibit radiolysis by adding thereto a pharmaceutical additive capable of inhibiting radiolysis, such as a sugar, a sugar alcohol and a sugar lactone, while the pH is kept at 2.0-5.9.

Radioactive diagnostic imaging agent

Unnatural amino acid radiolabeling precursor

A method for producing a radioactive diagnostic imaging agent containing a radioactivefluorine-labeled organic compound represented by the following formula (1): as an effective ingredient in which radiolysis of the effective ingredient is inhibited, involves providing a solution containing the radioactivefluorine-labeled organic compound represented by the above formula (1), adding an acid to the solution obtained in the first step in an amount sufficient for the solution to be kept within a pH of 2.0-5.9 in the following third step, and diluting the solution obtained in the second step in order to adjust the solution to a desired radioactive concentration within a pH of 2.0-5.9.

Method for production of radiation diagnostic imaging agent

A process is provided for producing a labeled precursor which is useful for production of a radioactive fluorine-labeled amino acid compound. In the reaction step for introducing a leaving group to a mixture of syn-form and anti-form of FACBC, a base is allowed to present in the reaction system to produce a syn-leaving group adduct, which is unreactive with the base and is highly stable, and an anti-leaving group adduct which can react with the base to form a water-soluble compound. By employing a purification method utilizing such a difference in solubility, the syn-leaving group adduct can be separated selectively. The base may be a linear- or branched-chain primary to tertiary alkylamine having 1 to 10 carbon atoms, a nitrogen-containing heterocyclic compound with 2 to 20 carbon atoms, and a nitrogen-containing hetero aromatic compound with 2 to 20 carbon atoms.

Process for production of precursor compound for radioactive halogen-labeled organic compound

A method for producing a radioactive diagnostic imaging agent which contains a radioactive halogen-labeled amino acid compound as an effective ingredient and has a composition that can inhibit radiolysis of the effective ingredient, thereby further improving stability, is provided. Disclosed is a method for producing a radioactive diagnostic imaging agent, comprising a solution preparation step of preparing a solution containing a radioactive halogen-labeled amino acid compound, and a dilution step of diluting the solution containing the radioactive fluorine-labeled organic compound in order to adjust radioactive concentration thereof, which further comprises an acid addition step of adding an acid to the solution containing the radioactive fluorine-labeled organic compound, after the solution preparation step and before the dilution step, wherein the acid is added in the acid addition step in an amount sufficient to adjust the pH of the solution resulting from the dilution step to 2.0-5.9, for example, in an amount corresponding to 0.40-2.8 mmol per 1 L of the solution resulting from the dilution step.

A compound that has affinity with amyloid, exhibits sufficiently rapid clearance from normal tissues, and is suppressed in toxicity such as mutagenicity is provided, which is represented by the following formula (1): or a salt thereof,wherein Ris a group selected from hydrogen, hydroxyl group, carboxyl group, sulfate group, amino group, nitro group, cyano group, an alkyl substituent with one to 4 carbon atoms or an alkoxy substituent with one to 4 carbon atoms; Ris a radioactive halogen substituent; and m is an integer of 0 to 2, and a low-toxic diagnostic agent for Alzheimer's disease comprising a compound represented by the above formula or a salt thereof is also provided.

Compound having affinity for amyloid

A process for production of a radioactive fluorine-labeled organic compound is provided which can improve the yield of radioactive fluorination. Provided is a process in which a compound represented by the following formula (1): (wherein Ris a straight or branched alkyl chain with 1-10 carbon atoms or an aromatic substituent, Ris a straight or branched haloalkylsulfonic acid substituent with 1-10 carbon atoms, a straight or branched alkylsulfonic acid substituent with 1-10 carbon atoms, a fluorosulfonic acid substituent or an aromatic sulfonic acid substituent, and Ris a protective group) is heated under stirring in an inert organic solvent in a presence of a phase transfer catalyst,F ions and potassium ions, so as to effect labeling with a radioactive fluorine, wherein the heating temperature is 40-90&#xb0; C., and the concentration of the phase transfer catalyst in the inert organic solvent is 70 mmol/L or more. Preferably, the molar ratio of the phase transfer catalyst is 0.7 or more relative to the compound of the formula (1), and the concentration of the compound of the formula (1) in the inert organic solvent is 50 mmol/L or more.

Process for production of radioactive-fluorine-labeled organic compound

Growing community of inventors

Tokyo, Japan

Akio Hayashi